TGFB1 and pancreatic neoplasm: Its core advantage lies in precisely capturing key interactions—such as apCAFs recruiting T cells via the CCL22-CCR4 pathway and M2 macrophages suppressing CD8+ T cells through the TGF-β/Smad pathway—by leveraging the tightly coupled interactions among pancreatic cancer stroma, tumor cells, and immune cells.